Interesting article. I wonder how much each company spends on acquisitions each year also. I recall reading an article not too long ago that said many of these companies are moving from research to acquisitions to keep their pipelines full. I wonder how many of these companies would spend 5 or even 10 billion+ for Kevetrin (once it gets to PIII)? Seems like the ROI would be an easier sell to their BOD than their existing research budget.